Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
Together, they discuss Rosana and Marty's recent publication regarding a virus-like element in our genome known as LINE-1. LINE-1, part of our "dark genome," was ignored as junk DNA for years, but is increasingly recognized to contribute to the pathology of autoimmunity, cancer, neurodegeneration, and aging. Rosana and Marty discuss how the discovery was made as well as how Rome Therapeutics is developing a platform to target LINE-1 and other factors that are part of the "dark genome" for the treatment of disease.
Additional reading:
Journal Club: Remodeling Oncogenic Transcriptomes with Ben Cravatt and Gene Yeo
Health System Partnerships with Tommy Ibrahim
From the Archives: The Art & Science of Biology's Future with Jennifer Doudna
The Power of a Platform Company with Josh Mandel-Brehm
Culture and Company Building with Sam Corcos
Payments & Payors: Fintech's Role with Kurt Adams
American Optimism with Joe Lonsdale
Going to Market in Healthcare: B2C2B
Advancing the Field of Immunotherapeutics
Healthspan, Lifespan, and the Biology of Aging
Payors and Providers Post-Pandemic
Using AI to Take Bio Farther
Expert AI as a Healthcare Superpower
Cultivated Meat: Challenges, Opportunities, Future
AI is Here. Now What?
Regulatory Trends in Telehealth
Demystifying DC: Opportunities for Collaboration
The Consolidated Drug Channel and Cash-Pay Drugs
Bio x Games: Is a Fun, Therapeutic Game Possible?
Carolyn Bertozzi and Degrading Drugs for Problematic Proteins
Create your
podcast in
minutes
It is Free